Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients

Schoonjans, A; Paelinck, BP; Marchau, F; Gunning, B; Gammaitoni, A; Galer, BS; Lagae, Lieven; Ceulemans, B

doi:10.1111/ene.13195

Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients

Author:

Schoonjans, A

Paelinck, BP ; Marchau, F ; Gunning, B ; Gammaitoni, A ; Galer, BS ; Lagae, Lieven ; Ceulemans, B

Keywords:

Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences, Neurosciences & Neurology, clinical trial, Dravet syndrome, epileptic encephalopathy, orphan drug, refractory epilepsy, serotonin, severe myoclonic epilepsy in infancy, TREATMENT-RESISTANT EPILEPSY, VALVULAR HEART-DISEASE, CANNABIDIOL, POPULATION, DRUGS, Adolescent, Adult, Anticonvulsants, Child, Child, Preschool, Drug Therapy, Combination, Epilepsies, Myoclonic, Female, Fenfluramine, Humans, Infant, Male, Prospective Studies, Seizures, Treatment Outcome, Young Adult, 1103 Clinical Sciences, 1109 Neurosciences, Neurology & Neurosurgery, 3202 Clinical sciences, 3209 Neurosciences

Abstract:

Dravet syndrome (DS) is a severe, drug-resistant epilepsy. Fenfluramine has been reported to have a long-term clinically meaningful anticonvulsive effect in patients with DS.